Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data
Authors:
Open Access
- 22 May 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0302382
Abstract
Background: The CLN2 Clinical Rating Scale evaluates disease progression in CLN2 disease, an ultra-rare, neurodegenerative disorder with late infantile onset. To validate the Clinical Rating Scale, a comparison with the Pediatric Quality of Life Inventory (PedsQL) was conducted utilising clinical trial data investigating cerliponase alfa use in CLN2 disease. Methods: Linear regression and mixed effects models were used to investigate the relationship between the Clinical Rating Scale and PedsQL using open-label, single-arm, phase 1/2 (NCT01907087) and ongoing extension study (NCT02485899) data of 23 children with CLN2 disease treated with cerliponase alfa for ≥96 weeks. Results: Correlations between the four Clinical Rating Scale domains were low. Linear mixed effects analyses showed significant correlation between PedsQL and Clinical Rating Scale (Total score or motor-language [ML] score adjusted p-values <0.05), driven by the relationship with the PedsQL Physical domain. A statistically significant relationship was identified between the Clinical Rating Scale motor domain and PedsQL (Total score: adjusted p-value = 0.048, parameter estimate [PE] = 8.10; Physical domain score: adjusted p-value = 0.012; PE = 13.79). Conclusions: Each domain of the Clinical Rating Scale provides unique information on disease state. Validity of the scale is supported by its relationship with the PedsQL. Among the four domains of the Clinical Rating Scale, motor has the highest correlation to PedsQL, suggesting motor function as a driver of patients’ quality of life. The lack of association between the remaining domains of the Clinical Rating Scale and PedsQL suggests that additional disease-specific measures may be needed to fully capture the quality of life impact of CLN2 disease. Trial registration: NCT01907087, NCT02485899.Keywords
Funding Information
- BioMarin Pharmaceutical
This publication has 16 references indexed in Scilit:
- Persistent treatment effect of cerliponase alfa in children with CLN2 disease: A 3 year update from an ongoing multicenter extension studyMolecular Genetics and Metabolism, 2019
- Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort studyThe Lancet Child & Adolescent Health, 2018
- Study of Intraventricular Cerliponase Alfa for CLN2 DiseaseNew England Journal of Medicine, 2018
- Management Strategies for CLN2 DiseasePediatric Neurology, 2017
- Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosisMolecular Genetics and Metabolism, 2016
- Neuronal Ceroid Lipofuscinosis and Associated Sleep AbnormalitiesPediatric Neurology, 2016
- Late infantile neuronal ceroid lipofuscinosis: Quantitative description of the clinical course in patients with CLN2 mutationsAmerican Journal of Medical Genetics, 2002
- The PedsQLTM 4.0 Generic Core Scales: Sensitivity, Responsiveness, and Impact on Clinical Decision-MakingJournal of Behavioral Medicine, 2002
- Specific substrate for CLN2 proteaseltripeptidylpeptidaseI assayEuropean Journal of Paediatric Neurology, 2001
- The PedsQL™: Measurement Model for the Pediatric Quality of Life InventoryMedical Care, 1999